ADVR to Present at the 2005 Annual Assembly of the AAHPM and HPNA.

YONKERS, N.Y. -- ADVR will Report Results on its Phase I/II Clinical Trial of AVR118 in Patients with AIDS

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that James T. D'Olimpio, M.D., has been invited to give an oral presentation at the 2005 Annual Assembly of the American Academy of Hospice and Palliative Medicine (AAHPM) and Hospice and Palliative Nurses Association (HPNA) to be held January 19-23, 2005, in New Orleans, LA.

Dr. D'Olimpio will deliver an oral presentation entitled, "Efficacious Reversal of AIDS Related Anorexia/Cachexia Syndrome: Final Results of a Phase I/II Study Using a Novel Peptide-Nucleic Acid Complex." The presentation is scheduled for 10:00 a.m. on January 22, 2005.

The presentation will report final results on the Phase I/II clinical trial of AVR118 in patients with AIDS. The 30-patient trial was conducted at the Kaplan Medical Center in Israel in cachetic AIDS patients.

"We are delighted that our abstract has been selected to be given as an oral presentation at such a prestigious conference," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "The joint meeting of the AAHPM and HPNA is the premier meeting of palliative medicine and all presentations given at the conference are selected based on peer review."

The American Academy of Hospice and Palliative Medicine (AAHPM) is the only organization in the United States for physicians dedicated to the advancement of hospice/palliative medicine, its practice, research and education. AAHPM members are physicians and other healthcare professionals from many medical specialties who are committed to furthering and fostering the practice of hospice/palliative care for the terminally ill and their families.

ADVR's AVR118 is a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which, to date, has demonstrated a very favorable safety profile, appears to stimulate the pro-inflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Data presented at the American Society of Clinical Oncology's (ASCO) annual meeting in June, 2004, showed that AVR118 appears to have activity against fatigue, loss of appetite, and weight loss in patients with HIV.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. ADVR, based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.